SALOFALK 500mg: tablets may show black spots due to the oxidation of the active ingredient.
Last updated
Summary
Product
SALOFALK 500mg
Issue
Health products - Product quality
What to do
Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
Distribution
National
Affected products
Brand |
Product Name |
Market Authorization |
Dosage Form |
Strength |
Lot numbers |
|---|---|---|---|---|---|
Abbvie |
SALOFALK 500mg |
DIN 02112787 |
Tablet (Delayed-Release) |
MESALAZINE 500mg |
247646A & 247647A |
Issue
Some tablets in the affected batches may show black spots due to the oxidation of the active ingredient.
What you should do
- Verify if your product is affected.
- Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Additional information
Background
Depth of recall: Retailers
Details
Original published date:
Alert / recall type
Health product recall
Category
Health products - Drugs
Companies
AbbVie Corporation 8401 Trans-Canada Highway, St-Laurent, QC, H4S 1Z1
Published by
Health Canada
Audience
General public
Healthcare
Industry
Distribution
National
Recall class
Type II
Identification number
RA-77329
Get notified
Receive emails about new and updated recall and safety alerts.